Drug interactions of cardiovascular drugs and their analysis in the patients of community pharmacy Author: Zuzana Vávrová1 Tutor: PharmDr. Josef Malý, Ph.D.1 1 Department of Social and Clinical Pharmacy, Charles University in Prague, Faculty of Pharmacy in Hradec Králové Introduction: Drug interactions represent a serious health problem and they cause many hospitalizations. Although their identification and documentation received a considerable attention, they remain unrecognized for many patients. Objectives: The goal of the thesis was to analyze serious drug interactions between cardiovascular drugs, to describe their management in clinical practice, which is useful during dispensation, and to evaluate occurrence of these drug interaction in a community pharmacy. Methodology: The information was gained from several databases and compared, and afterwards management of major drug interactions of betablockers and calcium channel blockers was created. Patients of a community pharmacy were screened for these drug interactions. The data were processed by frequency analysis. Results: In the theoretical part, 94 drug interactions were analysed. The total number of patients who received betablockers or calcium channel blockers in the community pharmacy was 525. Serious drug interactions described in this...

Drug interactions of cardiovascular drugs and their analysis in the patients of community pharmacy II. Author: Lenka Skořepová1 Tutor: PharmDr. Josef Malý, Ph.D.1 1 Department of Social and Clinical Pharmacy, Charles university in Prague, Faculty of Pharmacy in Hradec Králové Introduction: Drug interactions are a major cause of toxicity, side effects of drugs and increase the risk of harm to the patient. The pharmacist has an indispensable role in the process of minimizing risks and resolving of drug interactions. Objectives: The aim of the thesis was to carry out a research focused on drug interactions of selected groups of cardiovascular drugs and to describe their management in clinical practice, which could be used during dispensing medicine. Then was evaluated occurrence of these drug interactions in pharmacotherapy of community pharmacy patients. Methods: With the help of selected databases were described individual drug interactions of ACEI and created their management in clinical practice. Sample of patients of community pharmacy was screened for drug interactions. The data were processed by retrospective analysis. For 12 patients with drug interactions were processed case reports and tested solution of drug interactions with using of described management of drug interactions during the...

Title: The CVS method as a diagnostic of the cardiovascular system Objective: The aim of this thesis is to introduce the CVS (cardiovascular system) method as a potential diagnostic method to detect the overloading of the heart muscle, and thereby increased susceptibility to subsequent myocardial infarction and hypertension. Method: This thesis presents a data analysis on different groups of people, which were provided to us during the development of the CVS method. These were several groups of healthy individuals (athletes) and three groups of patients suffering from problems with the cardiovascular system (colaps conditions, obesity and hypertension). The groups were measured for their values of the heart rate and blood pressure at rest and during exercise on a bicycle ergometer. Subsequently the energy required to pump blood to the heart muscle and climbing speed pulse pressure depending on the heart rate was evaluated. Results: The CVS method shows differences in the energy consumption of the heart muscle in various groups of people. The results showed that at the same level of exercise the load of the heart muscle is higher by patients than by athletes. Considering the samples that we had available, the CVS method proved its diagnostic value when evaluating the overall effectiveness of the...

Short summary: Background: High cardiovascular risk in patients with chronic kidney disease is partly due to mineral dysbalance, microinflammation and oxidative stress. CKD patients accumulate traditional and non-traditional CV risk factors. FGF23, MMPs and PlGF belong among these non-traditional biomarkers of CV risk. FGF23 is a phosphaturic hormone and inhibitor of calcitriol synthesis. It is associated with vascular calcifications. Matrix-metalloproteinases (e.g. MMP-2, MMP-9) are proteolytic, proinflammatory enzymes, contributing to myocardial remodelation. Placental growth factor (PlGF) is a proangiogenic cytokine that is associated with LV hypertrophy in animal model. Plasmatic FGF23, MMPs and PlGF are elevated in CKD. Aim: We aimed to describe dynamic changes between several novel biomarkers of CV risk (FGF23, MMP-2, MMP-9 and PlGF) in CKD stages 1-5, to describe their mutual correlations and possible association with traditional CV risk markers. We studied possible association of laboratory and echocardiographic parameters in patients with CKD stages 2-4. Methods: In a cross-sectional study we evaluated 80 patiens with CKD 1-5 and 44 healthy controls. In a prospective study we evaluated echocardiographic and laboratory parameters in 62 patients with CKD 2-4 for an average study period of 36±10...

Short summary: Background: High cardiovascular risk in patients with chronic kidney disease is partly due to mineral dysbalance, microinflammation and oxidative stress. CKD patients accumulate traditional and non-traditional CV risk factors. FGF23, MMPs and PlGF belong among these non-traditional biomarkers of CV risk. FGF23 is a phosphaturic hormone and inhibitor of calcitriol synthesis. It is associated with vascular calcifications. Matrix-metalloproteinases (e.g. MMP-2, MMP-9) are proteolytic, proinflammatory enzymes, contributing to myocardial remodelation. Placental growth factor (PlGF) is a proangiogenic cytokine that is associated with LV hypertrophy in animal model. Plasmatic FGF23, MMPs and PlGF are elevated in CKD. Aim: We aimed to describe dynamic changes between several novel biomarkers of CV risk (FGF23, MMP-2, MMP-9 and PlGF) in CKD stages 1-5, to describe their mutual correlations and possible association with traditional CV risk markers. We studied possible association of laboratory and echocardiographic parameters in patients with CKD stages 2-4. Methods: In a cross-sectional study we evaluated 80 patiens with CKD 1-5 and 44 healthy controls. In a prospective study we evaluated echocardiographic and laboratory parameters in 62 patients with CKD 2-4 for an average study period of 36±10...